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Abstract
It is increasingly accepted that chronic inflammation participates in obesity-induced insulin resistance and type 2 diabetes
(T2D). Salicylates and thiazolidinediones (TZDs) both have anti-inflammatory and anti-hyperglycemic properties. The
present study compared the effects of these drugs on obesity-induced inflammation in adipose tissue (AT) and AT
macrophages (ATMs), as well as the metabolic and immunological phenotypes of the animal models. Both drugs improved
high fat diet (HFD)-induced insulin resistance. However, salicylates did not affect AT and ATM inflammation, whereas
Pioglitazone improved these parameters. Interestingly, HFD and the drug treatments all modulated systemic inflammation
as assessed by changes in circulating immune cell numbers and activation states. HFD increased the numbers of circulating
white blood cells, neutrophils, and a pro-inflammatory monocyte subpopulation (Ly6Chi), whereas salicylates and
Pioglitazone normalized these cell numbers. The drug treatments also decreased circulating lymphocyte numbers. These
data suggest that obesity induces systemic inflammation by regulating circulating immune cell phenotypes and that anti-
diabetic interventions suppress systemic inflammation by normalizing circulating immune phenotypes.
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Introduction
Sub-acute inflammation may play important roles in the
development of obesity-induced insulin resistance [1–4]. Adipose
tissue (AT) macrophages (ATMs) are believed to play a key role in
this process [5,6]. This is supported by observations that obesity
increases ATM numbers in humans and animal models; anti-
diabetic interventions decrease ATM numbers; and the ablation of
various genes in myeloid cells regulates the development of
obesity-induced AT inflammation and systemic insulin resistance.
Recent studies looking at ATMs have focused largely on the
immunophenotypes that are changed by obesity, and in particular
M1 and M2 phenotypes [7]. M1 macrophages mediate pro-
inflammatory responses by producing pro-inflammatory cytokines,
such as IL-6 or TNF-a, whereas M2 macrophages express unique
signature molecules, including anti-inflammatory genes (IL-10 and
TGF-b) and tissue repair/remodeling genes. M1 macrophages in
AT are often defined as being CD11c+, and numerous studies
have shown that obesity increases CD11c+ ATM numbers [7,8].
Hence, it is generally thought that obesity shifts the ATM balance
from M2 to a more M1 phenotype, and that anti-diabetic
interventions, such as thiazolidinediones (TZDs), reverse this shift
along with decreasing CD11c+ ATM numbers.
NFkB is an important regulator of inflammation. We have
previously shown that obesity activates the IKKb/NFkB pathway
in animals and that inhibition of this pathway by salicylates
improves obesity-induced insulin resistance [9,10]. Subsequently,
it was shown that systemic or myeloid cell-specific deletion of
IKKb or upstream molecules of the IKKb/NFkB pathway,
including TLR4, protects mice from the development of obesity-
induced insulin resistance [9,11]. These data show that NFkB
plays a critical role in the development of obesity-induced
inflammation and insulin resistance in murine models. We also
found that salsalate improves glycemic control in patients with
impaired glucose tolerance (IGT) or T2D and that this correlated
with the inhibition of NFkB in circulating leukocytes [12,13].
However, it has not been studied yet how salicylates affect AT and
ATM inflammation to improve insulin sensitivity. This question
was addressed in the present study.
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Materials and Methods
Animals
All animal experiments were conducted in the Joslin Diabetes
Center in accordance with the NIH guidelines under protocols
approved by the Institutional Animal Care and Use Committee of
the Joslin Diabetes Center. The mice were purchased from the
Jackson Lab and maintained under a standard light cycle (12 hr
light/dark) and allowed free access to water and food. They were
then fed normal chow (NC, 10% fat, D12450B, Research Diets,
Inc.) or a high fat diet (HFD, 60% fat, D12492, Research Diets,
Inc.) to induce insulin resistance. Salicylates (Sal, 3 g/kg diet) or
Pioglitazone (Pio, 100 mg/kg diet) was incorporated into a HFD
and administered for the indicated time. Metabolic phenotypes
were measured after overnight fasting. Insulin resistance index,
HOMA-IR, was calculated based on fasting glucose and insulin
levels [14].
Histology
After adipose tissues were fixed with formalin and imbedded in
paraffin, 4 mm thick tissue sections were prepared at the Joslin’s
Histology core. The slides were then stained with hematoxylin and
eosin and examined under an Olympus light microscope.
Flow Cytometric Analyses
Stromal vascular cells (SVCs) were isolated from epididymal AT
by using a well-established collagenase method [15]. RBCs were
lysed with ACK lysis buffer (Biowhittaker), after which the
remaining cells were stained with fluorophore-conjugated anti-
bodies specific for cell surface markers (Table S1). ATMs were
isolated as described (Figure S1). With regard to cells from the
blood, blood was collected from the tail vein in the presence of
5 mM EDTA, incubated with BD Fc Block, stained and lysed with
FACS Lysing Solution (BD Biosciences). The stained cells were
then analyzed by LSRII and the data were further analyzed by
using the FlowJo software. Complete blood counts (CBCs) were
measured by using a Hemavet 950 (Drew Scientific Inc.).
Real-time RT-PCR
Total RNA from AT and ATMs was prepared by using an
RNeasy Lipid Kit (Qiagen). RNA from ATMs was further
amplified with a MessageAmpII aRNA kit (Ambion). Thereafter,
cDNA was generated by using an Advantage RT-PCR kit
(ClonTech). Gene expression levels were determined by real-time
RT-PCR. The primer sequences and probes that were used are
listed in Tables S2 and S3.
Microarray Analysis
ATMs were sorted by FACS and their total RNA was isolated
by Trizol (Invitrogen) and amplified twice by using a Messa-
geAmpII aRNA kit (Ambion). The cRNA was then labeled with
biotin by using a MessageAmpII Biotin Enhanced aRNA kit
(Ambion). The resulting cRNAs were hybridized to M430 2.0
chips (Affymetrix) and the chips were scanned at the Joslin’s
Genomics Core. Thereafter, the data were processed, normalized,
analyzed, and visualized by GenePattern software modules.
Statistical Analysis
The results were expressed as means 6 S.E.M. The data were
analyzed by using unpaired t-tests. Differences were considered to
be statistically significant at p,0.05.
Results
Salicylates and Pioglitazone Improve Diet-induced Insulin
Resistance
We first compared the improvements of metabolic phenotypes
in diet-induced insulin resistance by salicylates and Pioglitazone.
Mice were fed a HFD for 8 weeks and then treated with salicylates
(3 g/kg diet) or Pioglitazone (100 mg/kg diet) for another 6 weeks.
Their metabolic phenotypes were then measured (Figs. 1A–D).
HFD increased the fasting body weight (FBW) by 43% and
Pioglitazone increased it further by,13%. However, the salicylate
treatments did not significantly change FBW, as compared to the
HFD group (Fig. 1A). HFD also increased the fasting blood
glucose (FBG) and fasting insulin levels (Fig. 1B & C), and
therefore insulin resistance as determined by the HOMA-IR
insulin resistance index (Fig. 1D). Both the salicylates and
Pioglitazone treatments improved insulin sensitivity by lowering
fasting blood glucose and insulin levels and therefore insulin
resistance index (Figs. 1B–D), although the improvements in
insulin sensitivity by Pioglitazone treatments were more profound
than by salicylate treatments.
Salicylates and Pioglitazone Regulate AT Inflammation
Differently
Recent studies strongly suggest that obesity and anti-diabetic
interventions, including TZDs, regulate AT inflammation by
modulating ATM phenotypes. Thus, the ability of salicylates to
alter AT inflammation by this mechanism was examined.
Hematoxylin and eosin staining of AT showed that HFD
increased immune cell infiltration, and that Pioglitazone decreased
this (Fig. 2A). In contrast, salicylate treatment was associated with
the same degree of immune cell infiltration as HFD on its own.
Real-time RT-PCR of the total AT for the macrophage-specific
marker genes Cd68 and Emr1 (F4/80) also indicated that HFD
increased ATM infiltration (Fig. 2B). Consistent with the histology
data (Fig. 2A), salicylate treatment did not change the HFD-
induced gene expression of Cd68 and Emr1. In contrast,
Pioglitazone decreased it by ,30%, which suggests that the latter
treatment decreased obesity-induced ATM infiltration. HFD also
increased the expression of M1 macrophage marker genes,
including Itgax (CD11c), Tnf (TNFa) and Il6 (Fig. 2C), but also
M2 macrophage marker genes, including Mrc1, Clec10a (Mgl1),
Il10, and Tgfb1 (TGF-b) (Fig. 2D). Although salicylates did not
alter the HFD-induced expression of the ATM marker genes
(which reflects its lack of effect on ATM numbers) (Fig. 2B), it
lowered Itgax and Mrc1 gene expression and increased Tgfb1 gene
expression. In contrast, Pioglitazone decreased the expression
levels of most M1 (pro-inflammatory) and M2 (anti-inflammatory)
genes. The two exceptions were Il6 and Il10: the gene expression
of both interleukins tended to be increased by Pioglitazone. These
data clearly showed that neither HFD nor the drug treatments
caused the AT to adopt an exclusively pro- or anti-inflammatory
status, or to shift wholly towards an M1 or M2 phenotype.
Since salicylate treatment increases circulating adiponectin
levels in humans [13], the AT Adipoq (adiponectin) gene expression
levels in the HFD-fed and treated mice were also measured. HFD
significantly decreased Adipoq levels by 87% compared to the NC
group. Salicylate treatment did not change this, whereas
Pioglitazone slightly but significantly increased it (Fig. 2E). HFD
also increased Lep (leptin) gene expression, whereas salicylate
treatments did not alter it. However, Pioglitazone dramatically
increased Lep expression levels by 2.9-fold compared to HFD
(Fig. 2E). This is consistent with the ability of Pioglitazone to
Systemic Inflammation in Obesity
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increase the fat weight (data not shown) and adipocyte size
(Fig. 2A).
Pioglitazone, but not Salicylates, Decreases ATM
Infiltration and Activation
The AT gene expression data suggested that salicylates do not
alter AT inflammation, including ATM infiltration. To assess this
further, the changes in ATM numbers and their activation were
quantitated by flow cytometric analysis (Fig. S1). When the
numbers of total AT immune cells (defined as CD45+) were
quantitated, HFD increased these cell numbers by 48% compared
to the NC group (Fig. 3A). Although salicylates did not change
these AT immune cell numbers, Pioglitazone caused them to drop
by 51% compared to the HFD group. Similar to the changes in
total AT immune cell numbers, HFD increased the numbers of
ATMs (defined as CD45+, NK1.12, CD49b2, CD902, B2202,
Gr-1lo, TER1192, CD11b+, and F4/80+, see Fig. S1) by 50% and
Pioglitazone normalized them to the level of the NC control group
(Fig. 3B). However, consistent with the CD68 and Emr1 gene
expression data (Fig. 2B), salicylates did not alter ATM numbers.
HFD also increased the number of putative M1 ATMs (defined as
CD11c+ ATMs) by 6.8-fold while Pioglitazone halved this number
and salicylates had no effect (Fig. 3C). Thus, Figures 2 and 3 show
clearly that salicylates do not alter HFD-induced ATM infiltration
whereas Pioglitazone suppress it.
Salicylates do not Alter HFD-induced ATM Gene
Expression Changes
Although salicylates did not change ATM infiltration, it is still
possible that they can regulate ATM inflammation by altering
ATM gene expression profiles. As it is not known which genes in
ATMs are regulated by salicylates, an Affymetrix microarray
technique was employed. The global gene expression profiles of
FACS-sorted ATMs from NC, HFD, and HFD/salicylate-treated
mice were first compared by using Volcano plots (Figs. 4A–C) and
mean class expression plots (Fig. S2). The genes that were
differentially expressed between the two populations (fold differ-
ence .2 and p,0.05) were shown as red dots if they were
upregulated and as blue dots if they were downregulated.
Compared to the NC group, 20.8% of the genes in the HFD
group were upregulated and 10.0% were downregulated (Fig. 4A
and Fig. S2A), and 25.8% of the genes in the Sal group were
upregulated and 12.6% were downregulated (Fig. 4B and Fig.
S2B). However, to our surprise, only a very small numbers of
genes were significantly differently regulated between the HFD
and Sal groups: only 0.7% of the genes in the Sal group were
upregulated while 1.0% were downregulated (Fig. 4C and Fig.
S2C). The top 10 genes that were differentially regulated in each
two-group comparison are listed in Table 1. It is worth noting that
only a few inflammatory mediator genes are on these lists.
Thereafter, the gene expression changes in HFD/NC vs. Sal/
NC were detected by using a Fold Change vs. Fold Change (FC/
FC) plot (Fig. 4D). In FC/FC plots, if genes of two populations
(here, HFD or Sal) are similarly regulated compared to the control
group (here, NC), most of the genes will be aligned along a
diagonal line. However, if they are differently regulated, the genes
will be away from the line. Figure 4D showed clearly that most of
the genes aligned well along the diagonal line. Only 53 genes were
differentially regulated (fold differences .2.0 and p,0.05) and
these are listed in Table 2. Again, they included very few
inflammatory mediator genes. These data together (Figs. 2–4)
showed strongly that salicylates do not improve obesity-induced
insulin resistance by modulating ATM recruitment or activation.
Figure 1. Treatment with Pio and/or Sal improves HFD-induced insulin resistance. C57BL/6 male mice (n = 8 per group) were given a HFD
starting at 7 weeks of age. After 8 weeks on HFD, the animals were fed for another 6 weeks with HFD alone or HFD plus salicylates (Sal, 3 g/kg diet) or
Pioglitazone (Pio, 100 mg/kg diet). The mice fed NC served as a control. After overnight fasting, the metabolic phenotypes were measured. The
fasting body weight (A), fasting blood glucose levels (B), fasting serum insulin levels (C), and the insulin resistance index as HOMA-IR (D) are shown.
*p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0082847.g001
Systemic Inflammation in Obesity
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Figure 2. Sal and Pio treatment regulate inflammatory mediator gene expression in total AT differently. Total epididymal AT samples
were obtained from the treatment study mice described in Figure 1 (n = 6–8 mice per group). AT inflammation was determined by assessing immune
cell infiltration with H&E staining (A) and by examining the expression levels of inflammatory mediator genes by using real-time RT-PCR. The genes
that were tested were macrophage-specific marker genes (B), M1 macrophage marker genes (C), M2 macrophage marker genes (D) and adipokine
genes (E). The expression of the housekeeping gene GAPDH was used to normalize gene expression. *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0082847.g002
Figure 3. Treatment with Pio, but not Sal, decreases ATM numbers, as determined by flow cytometric analyses. Epididymal AT samples
were prepared from the treatment study mice described in Figure 1 (n = 6–8 mice per group). The SVCs from the ATs of NC, HFD, Sal and Pio mice
were isolated, stained with antibodies against cell- and activation-specific surface markers, and analyzed by flow cytometry by using LSRII and FlowJo
software. ATMs were defined as CD45+, NK1.12, CD49b2, CD902, B2202, Gr-1lo, TER1192, CD11b+, and F4/80+. The cell numbers were normalized by
AT weight to compensate for AT weight differences between groups. The normalized immune cell (CD45+) numbers (A), ATM numbers (B), and
CD11c+ ATM numbers (C) are shown. *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0082847.g003
Systemic Inflammation in Obesity
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Figure 4. Microarray analysis of sorted ATMs from the NC, HFD and Sal groups. The ATMs were isolated from the ATs of the NC, HFD and
Sal groups of the treatment study (n = 2 mice per group). Their RNAs were purified, amplified and analyzed by Affymetrix microarray analysis. The
HFD vs. NC (A), Sal vs. NC (B), and Sal vs. HFD (C) gene expression profiles were compared by Volcano plots. Genes showing more than 2-fold
differences between groups that were significant (p,0.05) are indicated as red dots if they were upregulated and as blue dots if they were
downregulated genes. The genes in HFD and Sal mice that were differentially regulated relative to NC are shown in a FC/FC plot of (HFD vs. NC) vs.
(Sal vs. NC) (D). The genes that showed a more than 2-fold difference in this comparison that was significant (p,0.05) are indicated as red dots (HFD
down and Sal up), blue dots (HFD up and Sal down), cyan dots (HFD down and Sal further down), and pink dots (HFD up and Sal further up) (see
Table 2). Heat maps show the differential gene expressions of M1 genes (E), M2 genes (F) and NFkB target genes (G).
doi:10.1371/journal.pone.0082847.g004
Systemic Inflammation in Obesity
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Table 1. The top 10 genes that were differentially regulated in the HFD and Sal mouse groups.
Upregulated in HFD mice relative to NC mice
Genes NC HFD Sal
Matrix metallopeptidase 12 (Mmp12) 1.0060.10 285.4163.65 290.4164.66
Ring finger protein 128 (Rnf128) 1.0060.14 54.8463.88 47.3360.52
Glycoprotein (transmembrane) nmb (Gpnmb) 1.0060.11 27.9062.54 34.9861.38
Interleukin 7 receptor (Il7r) 1.0060.04 26.8960.74 46.2960.97
Glutaminyl-peptide cyclotransferase (glutaminyl cyclase) (Qpct) 1.0060.29 26.4361.09 24.2462.09
Lipoprotein lipase (Lpl) 1.0060.04 24.7760.50 27.0760.23
V-set and immunoglobulin domain containing 8 (Vsig8) 1.0060.07 24.1661.25 28.7560.25
Fibroblast growth factor 13 (Fgf13) 1.0060.29 20.6660.77 12.7360.46
Coagulation factor VII (F7) 1.0060.10 20.2961.21 41.0060.24
Cathepsin K, (Ctsk) 1.0060.04 20.1760.30 19.9360.93
Upregulated in Sal mice relative to NC mice
Genes NC HFD Sal
Matrix metallopeptidase 12 (Mmp12) 1.0060.10 285.4163.65 290.4164.66
Ring finger protein 128 (Rnf128) 1.0060.14 54.8463.88 47.3360.52
Interleukin 7 receptor (Il7r) 1.0060.04 26.8960.74 46.2960.97
Coagulation factor VII (F7) 1.0060.10 20.2961.21 41.0060.24
Glycoprotein (transmembrane) nmb (Gpnmb) 1.0060.11 27.9062.54 34.9861.38
V-set and immunoglobulin domain containing 8 (Vsig8) 1.0060.07 24.1661.25 28.7560.25
Lipoprotein lipase (Lpl) 1.0060.04 24.7760.50 27.0760.23
Glutaminyl-peptide cyclotransferase (glutaminyl cyclase) (Qpct) 1.0060.29 26.4361.09 24.2462.09
Potassium intermediate/small conductance calcium-activated channel, subfamily N,
member 4 (Kcnn4)
1.0060.03 16.1160.50 22.1860.30
Protocadherin 7 (Pcdh7) 1.0060.07 18.4162.66 21.3261.68
Upregulated in Sal mice relative to HFD mice
Genes NC HFD Sal
immunoglobulin lambda chain, constant region 3 (Igl-C3) 1.1660.05 1.0060.04 6.4560.49
Dedicator of cytokinesis 7 (Dock7) 0.8260.29 1.0060.29 4.2360.56
Kinesin family member 13B (Kif13b) 0.8660.05 1.0060.02 4.1660.36
Immunoglobulin lambda chain, constant region 2 (Igl-C2) 0.1560.04 1.0060.04 3.3860.11
NFkB inhibitorj (Nfkbiz) 0.9660.01 1.0060.09 3.0460.03
Forkhead box P1 (Foxp1) 1.8360.23 1.0060.02 2.9960.26
Eosinophil-associated, ribonuclease A family (Ear) 0.3460.00 1.0060.00 2.9760.13
Lactate dehydrogenase C (Ldhc) 0.9660.00 1.0060.05 2.9460.37
Acyl-Coenzyme A binding domain containing 3 (Acbd3) 1.5060.04 1.0060.03 2.9060.14
Cut-like homeobox 1 (Cux1) 2.0260.00 1.0060.05 2.9060.20
Downregulated in HFD mice relative to NC mice
Genes NC HFD Sal
Aldo-keto reductase family 1, member B7 (Akr1b7) 1.0060.12 0.0260.00 0.0160.00
Protamine 1 (Prm1) 1.0060.06 0.0260.00 0.0260.00
Dysteine-rich secretory protein 1 (Crisp1) 1.0060.02 0.0360.00 0.0260.00
Clusterin (Clu) 1.0060.06 0.0360.00 0.0460.00
Carboxylesterase 3 (Ces3) 1.0060.06 0.0360.00 0.0460.00
Complement factor D (adipsin) (Cfd) 1.0060.08 0.0460.00 0.0460.00
Uroplakin 3B (Upk3b) 1.0060.07 0.0460.00 0.0760.00
Systemic Inflammation in Obesity
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HFD does not Categorically Affect M1, M2, and NFkB
Target Gene Clusters
Microarray dataset was analyzed further to determine molec-
ular differences of the ATMs from the HFD and NC groups. The
current paradigm in the field is that obesity polarizes the ATMs
from M2 macrophages into M1 macrophages. However, the heat
map for the M1 gene cluster showed clearly that HFD did not
exclusively and categorically upregulate the expressions of the M1
cluster genes (Fig. 4E and Table S4A): while one-third of the M1
cluster genes were indeed upregulated by HFD (e.g. Il7r and Itgax),
almost equal numbers of genes were not changed by HFD (e.g.
Il12a and Ccl2) or even downregulated (e.g. Il6 and Ptgs2). The M2
and NFkB target genes clusters also showed very similar patterns
(Figs. 4F, 4G, and Tables S4B and S4C). Consistent with the
previous results, salicylates did not significantly affect the
expression of these genes. These data demonstrate clearly that
ATMs cannot be exclusively categorized as either M1 or M2, as
has been suggested previously. They also suggest strongly that with
regard to the development of obesity-induced inflammation,
individual inflammatory mediator genes must be studied instead
of seeking to categorize ATMs into M1 or M2 phenotypes.
Salicylates and Pioglitazone Regulate the M1 and M2
Gene Expression of ATMs Differently
Next, the M1 and M2 gene expressions of the ATMs in the
microarray data were verified by using real-time RT-PCR and
compared to the expression of M1 and M2 genes in the Pio ATMs
(Fig. 5). Consistent with the microarray data, not all M1
macrophage marker genes were upregulated by HFD, nor were
all M2 macrophage marker genes downregulated by HFD. For
example, HFD increased Tnf gene expression but decreased Il6
gene expression. Moreover, HFD downregulated Clec10a (Mgl1),
Mgl2 and Mrc1 expression while upregulating Il10 and Arg1 gene
expression. These data confirm the notion that HFD does not
exclusively polarize ATMs into M1 or M2 phenotypes. Salicylates
and Pioglitazone also regulated the expression of these genes in a
manner that was inconsistent with the M1/M2 paradigm. For
example, while Pioglitazone decreased the effect of HFD on the
gene expression of Itgax and Tnf and increased Il6 gene expression,
it also increased the HFD-elevated Arg1 gene expression further.
Moreover, salicylates increased the expression levels of the pro-
inflammatory Itgax and Tnf genes as well as the anti-inflammatory
Il10 gene. These data confirm that HFD and anti-diabetic
Table 2. The genes that were up- or down-regulated in HFD and Sal mice relative to NC mice.
Genes that were upregulated in HFD and downregulated in Sal (red dots in Fig. 4D)
Genes NC HFD Sal
Igk constant C/V28 region (Igk-C/Igk-V28) 0.1260.03 1.0060.01 0.2360.00
Ubiquitin carboxy-terminal hydrolase L1 (Uchl1) 0.2360.01 1.0060.03 0.2760.03
Ig joining chain (Igj) 0.1560.02 1.0060.08 0.3160.02
Ser/Cys peptidase inhibitor (Serpinb9b) 0.1060.02 1.0060.03 0.3260.01
Matrix metallopeptidase 3 (Mmp3) 0.1060.00 1.0060.00 0.3560.01
Lysosomal acid lipase A (Lipa) 0.1860.02 1.0060.07 0.3660.01
PRP19/PSO4 mammalian homolog (Prpf19) 0.2860.01 1.0060.03 0.3660.01
Alpha fetoprotein (Afp) 0.1060.01 1.0060.06 0.3860.05
Rock1 (Rock1) 0.4660.04 1.0060.08 0.4060.01
Thymus cell antigen 1j (Thy1) 0.3360.01 1.0060.03 0.4060.03
Isochorismatase domain containing 1 (Isoc1) 0.4360.05 1.0060.04 0.4160.01
Interferonc (Ifng) 0.2960.03 1.0060.09 0.4260.03
Histone cluster 1H2a (Hist1h2a) 0.3460.06 1.0060.03 0.4360.01
Arylacetamide deacetylase-like 1 (Aadacl1) 0.1960.01 1.0060.02 0.4460.02
Glia maturation factorb (Gmfb) 0.4460.06 1.0060.09 0.4460.04
BMP-binding endothelial regulator (Bmper) 0.4260.01 1.0060.03 0.4460.03
Vesicle-associated membrane protein B and C (Vapb) 0.3460.00 1.0060.05 0.4660.00
ADP-ribosylation factor-like 6 interacting protein 5 (Arl6ip5) 0.3960.06 1.0060.00 0.4860.03
IGF-2 mRNA binding protein 2 (Igf2bp2) 0.1060.01 1.0060.03 0.1060.01
Genes that were downregulated in HFD and upregulated in Sal (blue dots in Fig. 4D)
Genes NC HFD Sal
Cut-like homeobox 1 (Cux1) 2.0260.00 1.0060.05 2.9060.20
Stat 3 (Stat3) 4.7160.05 1.0060.04 2.7060.00
Nischarin (Nisch) 4.0860.48 1.0060.07 2.6660.06
RAB43 (Rab43) 2.3760.02 1.0060.00 2.4860.18
Metastasis suppressor 1 (Mtss1) 4.4760.65 1.0060.02 2.2760.04
doi:10.1371/journal.pone.0082847.t002
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interventions regulate inflammatory mediator genes in an individ-
ual and independent manner rather than as M1 or M2 clusters.
HFD Induces Systemic Inflammation by Regulating
Circulating Leukocytes, and Salicylates and Pioglitazone
Normalize this
This study showed that salicylates did not improve insulin
sensitivity by targeting the AT or ATMs. However, it was
observed that the salicylates strongly regulated circulating immune
cells. Analysis of CBCs revealed that HFD increased circulating
WBC and neutrophil numbers and that salicylates and Pioglita-
zone normalized these numbers to the numbers seen in the NC
group (Fig. 6A). The drug treatments also lowered circulating
lymphocyte numbers, although HFD did not change them. We
further examined the effect of obesity and the drug treatments on
the changes in the lymphocyte subtype numbers in the circulation
by using flow cytometry analyses (Fig. S3). We found that obesity
and the anti-diabetic drugs changed the circulating lymphocyte
subsets: HFD increased the numbers of CD4 T cells and B cells
and Sal and Pio treatments reduced the numbers of CD4 and CD8
T and B cells, although these changes did not achieve statistical
significance.
None of the treatments changed the circulating monocyte
numbers (Fig. 6A). However, it has been well documented that
monocyte subpopulations that are isolated on the basis of their
Ly6C expression play an important role in regulating inflamma-
tion in various disease models [16]. The Ly6Chi monocyte
subpopulation expresses CCR2, moves into the local inflammatory
sites in a MCP1-dependent manner, and then differentiates into
macrophages that regulate inflammation. Hence, Ly6Chi mono-
cytes are often denoted as an inflammatory monocyte subset. In
contrast, the Ly6C- monocytes express CX3CR1 instead of CCR2
and are considered to be the residential monocytes. Flow
cytometric analysis showed that HFD dramatically increased the
size of the Ly6Chi monocyte subpopulation without changing the
numbers of the Ly6Clo or Ly6C- populations (Figs. 6B and C and
Fig. S4). Sal and Pio treatments decreased the size of the Ly6Chi
population to the level of the NC group while marginally
increasing the Ly6C- subpopulation. Pioglitazone also significantly
lowered the Ly6Clo population number (Fig. 6C). These data show
clearly that HFD treatment increased the numbers of circulating
WBCs, neutrophils, and the Ly6Chi pro-inflammatory monocytes,
and that both anti-diabetic interventions normalized this systemic
inflammation.
Figure 5. Pio and Sal regulate the M1 and M2 gene expressions of sorted ATMs differently. ATMs were sorted from the ATs of the NC,
HFD, Sal and Pio groups in the treatment study described in Figure 1 (n = 6–8 mice per group). Their RNAs were then purified, amplified and analyzed
by real-time RT-PCR. The genes that were tested were M1 (A) and M2 (B) genes. The housekeeping gene GAPDH was used to normalize gene
expression. *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0082847.g005
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Discussion
The main aim of this study was to examine the effect of
salicylates on AT and ATM inflammation and to compare this
with the effects of Pioglitazone. We used Pioglitazone as a control
in this study because it has previously been shown to suppress
obesity-induced AT inflammation, especially of ATMs. However,
TZDs including Pioglitazone have additional effects on adipocyte
differentiation and the redistribution of lipids from ectopic sites
like the liver into AT, which improve insulin sensitivity and
glycemic control. We were surprised by the lack of an effect of
salicylates on either AT or ATM inflammation, under conditions
where Pioglitazone decreased ATM numbers and suppressed
inflammatory gene expression in ATMs. This was shown by the
inflammatory mediator gene expression profiles of AT and sorted
ATMs, the flow cytometric analyses of ATMs, and most
conclusively, the microarray gene expression profile analyses.
Thus, the present study suggests that the improvement of insulin
sensitivity by salicylates does not require the suppression of HFD-
induced AT or ATM inflammation.
These observations lead to the question: what is the target of
salicylates for the suppression of HFD-induced inflammation?
Because obesity, insulin resistance, and T2D are systemic diseases,
we postulated that obesity-induced inflammation is also systemic,
namely, that obesity changes the numbers and/or activations of
the circulating (systemic) immune cells. Indeed, HFD significantly
increased the numbers of circulating immune cells, including
neutrophils. Total monocyte numbers were not changed by HFD
or the treatments. However, it is now well established that Ly6Chi
monocytes play a pro-inflammatory role in various inflammatory
diseases, including atherosclerosis [17,18], and we have shown that
HFD also increases the Ly6Chi monocyte subpopulation. Further-
more, salicylates and Pioglitazone decreased the numbers of
WBCs, neutrophils, lymphocytes and Ly6Chi monocytes while
concurrently improving insulin sensitivity.
Interestingly, our clinical study showed that salicylates halve the
NFkB activity in circulating immune cells [12]. This phenomenon
coincides with the salicylate-induced 50% decrease in Ly6Chi
monocyte numbers compared to the HFD group in the present
study (Fig. 6C). Notably, Ly6Chi monocytes express CCR2, which
mediates the migration of monocytes into local inflammatory sites.
However, the present study showed that salicylates, unlike
Pioglitazone, did not decrease ATM infiltration in obesity.
Consequently, the macrophage infiltration of the liver was assessed
in the present study by measuring macrophage marker gene (Cd68
and Emr1) expression by using real-time RT-PCR (Fig. S5).
However, while Pioglitazone decreased HFD-induced macro-
phage infiltration into the liver, salicylates did not. This suggests
that salicylates may not regulate monocyte migration into local
tissues. How, then, do obesity and salicylates regulate systemic
inflammation and insulin resistance? One possibility is that
circulating activated immune cells produce inflammatory cyto-
kines. It has been established that Ly6C+ monocytes can produce
inflammatory cytokines [16,19]. In addition, neutrophils are fully
activated when they egress from the bone marrow and therefore
can immediately produce inflammatory cytokines in the circula-
tion in response to environmental insults such as obesity. Although
the absolute amounts produced by these circulating cells may be
Figure 6. Obesity induces systemic inflammation by increasing the numbers of circulating immune cells and a pro-inflammatory
monocyte subset, and Sal and Pio treatment reverse these increases. The CBCs of the mice from the treatment study described in Figure 1
were determined by using a Hemavet hematology analyzer (A). The circulating Ly6C-, Ly6Clo, and Ly6Chi monocyte subpopulations were analyzed by
flow cytometric analysis (B and C). *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0082847.g006
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less than that generated by tissue resident cells including ATMs or
AT neutrophils, there are far greater numbers of circulating
immune cells than local immune cells. Therefore, the total
cytokine output of the circulating immune cells may be much
greater than that of tissue resident leukocytes. Obesity and anti-
diabetic drugs may impact inflammation and insulin resistance
through systemic effects on circulating immune cell numbers and
activation. To test this, we examined the circulating cytokine levels
in the NC, HFD, Sal and Pio groups by using multiple assay
methods, including the Luminex system. However, in our hands,
many cytokines in the circulation, including IFNc, IL-4 and IL-15,
are under the limits of detection, and others (IL-1b, IL-6, TNFa
and RANTES) did not differ regardless of diet or treatment (data
not shown). It may be that because obesity-induced inflammation
is low grade and subacute, activated immune cells may produce
much lower levels of inflammatory mediators than the current
systems (ELISA or Luminex system) can detect. Another possibility
is that we did not select the right inflammatory mediators for this
experiment because obesity-induced inflammation may differ
markedly from the classical inflammation induced by infections
and autoimmunity. There are more than 100 different inflamma-
tory mediators (including cytokines) that play distinctive roles in
response to the various inflammatory challenges. However, with
the current assay systems, we could measure only limited numbers
of cytokines that we have chosen based on the studies from the
classical immunological studies. Therefore, it is possible that
obesity and anti-diabetic treatments regulate different types of
non-classical inflammatory mediators that we did not assess in this
study.
Nevertheless, clinical studies support this and are consistent with
a hypothesized role for circulating leukocytes in the pathogenesis
of insulin resistance. Epidemiological studies have shown that high
circulating neutrophil and WBC counts predict incident T2D and
atherosclerosis, and poor outcomes after myocardial infarctions
and stroke [20–26]. Moreover, the TINSAL-T2D clinical trial
showed that salicylates lowers WBC, neutrophil and lymphocyte
counts in patients with T2D concomitant with improvements in
glycemic control [27]. Of the inflammatory variables tested in
TINSAL-T2D, changes in circulating leukocyte counts were
among the most robust. Clinical trials have also shown that
Pioglitazone lowers circulating leukocyte counts along with
improving glycemic control [28–30]. However, these earlier
findings were largely ignored, perhaps because the counts
remained well within normal ranges. Future studies are needed
to assess potential roles of circulating leukocytes on insulin
resistance as well as other cardiometabolic complications of
obesity.
These findings together suggest strongly that salicylates improve
insulin resistance and glycemic controls by regulating systemic
inflammation. However, it is still possible that salicylate’s
improvements of dysglycemia may be through multiple mecha-
nisms, including mechanisms other than suppression of obesity-
induced inflammation.
The microarray data in the present study not only confirmed
conclusively that salicylates did not target ATMs, they also
revealed several other interesting findings that may be underap-
preciated in the field of obesity research. First, these data suggest
strongly that ATMs cannot be categorized according to the binary
system of M1 and M2 phenotypes; instead, they should be
categorized on the basis of individual inflammatory mediator
genes (e.g. Tnf vs. Il6). Second, the changes in the expression of
genes in the AT were much greater than those of sorted ATMs: for
example, while sorted ATMs from HFD-fed mice expressed ,2-
fold higher levels of Tnf relative to NC mice, the total AT from
these HFD-fed mice expressed ,25-fold higher levels of Tnf. This
is mainly due to the compounding effects of increased ATM
numbers and their increased gene expression levels, and it may be
one of the mechanisms by which obesity amplifies AT inflamma-
tion. Moreover, other immune cells may also contribute to the
degree of AT inflammation; this may be responsible for the
differential gene expression of sorted ATMs and total AT
regarding cytokines such as Il6.
In summary, salicylate improved obesity-induced insulin resis-
tance without affecting AT and ATM inflammation. However, it
was also observed that obesity induced systemic inflammation by
modulating the numbers of circulating WBCs, neutrophils, and the
Ly6Chi pro-inflammatory monocytes, and that salicylates and
Pioglitazone suppressed this systemic inflammation, as shown by
their ability to reverse the HFD-induced changes in the numbers
of circulating immune cells and their subpopulations. Hence, these
data may provide new insights into how HFD and anti-diabetic
drugs regulate inflammation, namely, by modulating systemic
inflammation.
Supporting Information
Figure S1 Gating strategy for flow cytometric analysis of ATMs.
After SVCs were isolated from AT by using a collagenase method,
they were stained with antibodies against cell-specific markers and
subjected to flow cytometric analysis with LSR II. The data were
analyzed by FlowJo software with the following gating strategy.
After the appropriate cells were selected by FSC/SSC gating, the
aggregated cells were removed by FSC-W/SSC gating (A). The
live cells were then selected by propidium iodide (PI)- staining (B).
Thereafter, the total leukocytes were selected as CD45+ (C). The
lymphocytes and RBCs were excluded by removing the NK1.1+
(NK and NKT cells), CD49b+ (NK cells), B220+ (B cells), CD90+
(T cells), and TER119+ (RBC) cells (D). The neutrophils were
removed by eliminating the Gr-1hi cells (E). Finally, ATMs were
determined by identifying the CD11b+ and F4/80+ cells (F).
Hence, in this gating strategy, ATMs were defined as CD45+,
NK1.12, CD49b2, CD902, B2202, Gr-1lo, TER1192, CD11b+
and F4/80+.
(TIF)
Figure S2 Mean Class Expression comparison of the microarray
data in Figure 4. On the basis of the microarray data of Figure 4,
the following mean class expression profile comparisons were
performed: HFD vs. NC (A), Sal vs. NC (B), and Sal vs. HFD (C).
Genes that showed a more than 2-fold difference between groups
that was significant (p,0.05) were indicated as red dots if they
were upregulated and as blue dots if they were downregulated.
(TIF)
Figure S3 Treatment with Pio and Sal decreases circulating T
and B cells, as determined by flow cytometric analyses. Blood was
collected from the tail vein in the presence of 5 mM EDTA,
incubated with BD Fc Block, stained with antibodies and lysed
with FACS Lysing Solution (BD Biosciences). The cells were then
analyzed with LSR II and the data were analyzed by FlowJo
software.
(TIF)
Figure S4 Gating strategy for flow cytometric analysis of
circulating monocytes. Whole blood was incubated with FcBlock
to block the non-specific binding of Abs and then stained with
antibodies against cell-specific surface markers. After staining, the
RBCs were removed by lysing with FACS Lysing Solution (BD
Biosciences). The cells were then analyzed with LSR II. The data
were analyzed by FlowJo software with the following gating
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strategy. Aggregated cells were first removed by FSC-W/SSC
gating (A). The total leukocytes were identified by positivity for
CD45 (B). The neutrophils were removed on the basis of their Gr-
1hi status (C). The lymphocytes and RBCs were excluded by
removing the NK1.1+ (NK and NKT cells), CD49b+ (NK cells),
B220+ (B cells), CD90+ (T cells), and TER119+ (RBC) cells (D).
Monocytes were selected on the basis of their CD11b positivity (E).
The monocyte subpopulations were determined on the basis of
their Ly6C expression levels (F).
(TIF)
Figure S5 Pio, but not Sal, treatment decreased HFD-induced
macrophage infiltration in the liver. Liver samples from the
treatment study described in Figure 1 were prepared (n= 6–8 mice
per group). mRNA was purified and the expression levels of
macrophage-specific genes were determined by real-time RT-
PCR. Gene expression was normalized by using the cyclophilin
gene. *p,0.05; **p,0.01.
(TIF)
Table S1 Cell surface markers that were used for the
flowcytometry analyses.
(TIF)
Table S2 TaqMan probes used in this study.
(TIF)
Table S3 Primer sequences used in this study.
(TIF)
Table S4
(ZIP)
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